$CYTR was removed from Russell 2000 and 3000 indexes yesterday because market cap is below the minimum that was set on "Rank Day" back in May. For 2017 that minimum market cap is set at $144 mil. Share price must also be above $1.00. Removed also from the Microcap Index because share price is below a dollar (min. MC in this Index is only $30 mil). So the various funds that mirror these indexes sold off their holdings yesterday of companies that did not meet these criteria on Rank Day. Looks like the process went smoothly, although I'd really like to know who all bought those shares at .6727, .6728 & .6729.
Here you go people...time to divert your focus from Cytrx to Portola. AF and the short squad have torn into Portola and Cytrx with equal vigor. Watch the short st*t show after after a controversial FDA approval. Watch the pop and drop as the stock spikes when the shorts cover and comes back to planet earth after all of Portola's John's, J's, Dewd's and Lou's take out a second mortgage to cover. Watch how the stock builds for the Andexxa Alpha approval and inevitable Sept-Dec buyout.
Our short friends will tell you that I am delusional, because this doesn't happen to $.70 stocks. Unless that stock is Celator and that is an exception to AFs rule, as is Puma and now Portola. I think the AF-Rattain rule is now at about 50-50. You might better over betting red on the roulette wheel than on Feuerstein's basic investment premise. Maybe this is why he is no longer with the street? Inevitably, one of his new co-workers will have to put a giant crow on a skewer on his desk Monday morning. Hopefully, somebody in the office will post an iphone video of him scurrying to his desk wearing the $2500 armani he was forced to buy when he chose to take the desk job. The beautiful thing for Adam is that he can cut, paste, find and replace CPXX with PBYI with PTLA and eventually CYTR for his next "I was wrong" announcement. Yes Adam, it is possible to return the Armani to Men's Warehouse if things don't work out. It's only been a month...
Stay patient Cytrx longs, our time will come...
Who thinks dewd is the biggest loser here? Lololololo
All eyes on next week's results!! I believe they will be positive. Glta!!
Few more steps to reach $1 and then this stock will be rapidly nearing $6 before you know it. We are getting to the final destination for CYTR to be bought up for $35.
I don't have all the fancy screens that you all have. Can some one tell me, we're the 7 million shares at the last minute of trading bought or sold? Please only reply with a serious answer. Thanks
Looks like the selling was the deletion of CytRx from the Russell 3000 but then who was picking up the shares?
dewd Don't bother. Some of these people are out of touch. I got a thumbs down for what I said about the chart. Its like if they were lost on the trail they would mash their compass because it didn't agree with the heading they want. Only in the CYTR world does that make any sense!
above 70 today
Something has to be going on I'm seeing about 9 million shares traded in after hours
Wow! Did anyone else see the trade of 6,921,836 shares post at 4:00 p.m. at .6727 per share? That's a $4,656,319.00 trade. That explains a lot of how and why we closed today.
Hoping for partnership announcement before the end of June.
Lets Fast Forward to Monday morning.... Day traders who bought in and didn't book their profits today, and most other who swing trade, will check their watch list. They will see no news and no new filings. At that point they will cash out to preserve their gains. The stampede will be swift and you'll be lucky to get out before the gap down. No ONE books a profit until the exit
exit strategy: sell when I feel like I have sufficiently made as much money as I can make
I don't know why CYTRX has been so hush on this SCLC trial. Not a hint or a clue of what's going on except for a few that have talked to Haen. The last time they even talked about SCLC efficacy is in 2015 when the trial was being designed. It's driving me nuts and puts more pressure on the company than ever before. It's make or break, put up or shut up, go to market or go home time in my opinion. I don't know how the SCLC study could go bad at this point but I'm somehow afraid it might.
"In prior Phase 1 trials, we have seen encouraging evidence of SCLC patients with tumor shrinkage and prolonged stable disease. Our previous data in relapsed or refractory solid tumor patients indicates that the dose of aldoxorubicin being administered to these patients is well tolerated and without any treatment-limiting side effects. Up to 21 cycles (4.8 grams/m2) have been given to one patient with small cell lung cancer with minimal side effects and good anti-tumor activity."